Request Trial
istock-506815322_artjazz
artjazz / iStockphoto.com
21 April 2022Alex Baldwin

Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Settled expectations, the six-year rule, and developments in USPTO policy
6 November 2026   Uncertainty over whether a patent can be challenged through inter partes review at the USPTO has only increased since the discretionary denial policy was introduced, so how should companies plan? Mauricio Uribe and Maria Anderson of Davis Wright Tremaine explain.
Regulation & Industry
Regulatory and patent teams must align, say Amgen, Genentech, ORIC
5 November 2026   Things can go “sideways pretty quickly” if the two sides of pharma protection are not communicating with each other, said a senior panel of industry counsel at LSPN Fall.
Regulation & Industry
EPO starts using AI for minutes but no access to transcripts for parties
5 November 2026   From November 1, oral proceedings before a Board of Appeal can be audio-recorded and transcribed using artificial intelligence, but any material generated will be kept internal and will not form part of the file or be made available


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

Regulatory and patent teams must align, say Amgen, Genentech, ORIC
EPO starts using AI for minutes but no access to transcripts for parties
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
Dykema’s new trademark pro will be a ‘tremendous asset’ to clients
In-house counsel rethink patent filing strategies as costs mount
Fenwick hires NY partner to advise on regulatory matters
UK unveils £1bn sector investment push after recent setbacks
Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos